Alexander Y. Walley, MD

Professor, Medicine

Alexander Walley
801 Massachusetts Ave Crosstown Center

Biography

Dr Walley is Professor of Medicine and an addiction expert at Boston Medical Center and Boston University School of Medicine. Dr Walley has conducted multiple studies related to the opioid crisis and the integration of addiction specialty care and general medical care. He has served as PI on a CDC-SAMHSA-Epi-AID investigation of the surge in fentanyl-related overdose, a CDC-funded study of the Massachusetts OEND program which demonstrated community-level reductions in overdose death rates, and a SAMHSA-funded program that integrated addiction treatment into the clinical care of people with/at risk for HIV. He has worked as Co-I with addiction, overdose, and HIV expertise on NIDA and NIAAA-funded clinical trials and cohort studies.

Dr Walley is the director of the Boston Medical Center Addiction Medicine Fellowship program, as well as the director the NIDA-funded Fellow Immersion Training program in Addiction Medicine, which trains 5 subspecialty fellows each year to integrate addiction science into their subspecialty research. He provides primary care and addiction medicine consultations in the HIV primary care clinic at Boston University School of Medicine/BMC where he leads the FAST PATH (Facilitated Access to Substance abuse Treatment for Prevention and Treatment of HIV) program. Dr Walley co-founded and provides care on the inpatient addiction consult service at Boston Medical Center, which regularly provides consultation for patients admitted to the hospital who use alcohol and substances. Lastly, Dr Walley has been the medical director of the Massachusetts Opioid Overdose Prevention program since it started in 2007. They have trained and equipped over 100,000 people in the community with naloxone rescue kits, culminating in over 25,000 documented overdose rescues.

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University School of Medicine
  • Courtesy Staff Privileges, Medicine, Boston Medical Center

Education

  • Johns Hopkins University School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Harvard College, AB

Classes Taught

  • GMSMS710

Publications

  • Published on 8/15/2022

    Jawa R, Walley AY, Wilson DJ, Green TC, McKenzie M, Hoskinson R, Bratberg J, Ramsey S, Rich JD, Friedmann PD. Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. J Acquir Immune Defic Syndr. 2022 Aug 15; 90(5):546-552. PMID: 35587832.

    Read at: PubMed
  • Published on 8/1/2022

    Crable E, Jones DK, Walley AY, Hicks JM, Benintendi A, Drainoni ML. How Do Medicaid Agencies Improve Substance Use Treatment Benefits? Lessons from Three States' 1115 Waiver Experiences. J Health Polit Policy Law. 2022 Aug 01; 47(4):497-518. PMID: 35044466.

    Read at: PubMed
  • Published on 7/29/2022

    Weisenthal K, Kimmel SD, Kehoe J, Larochelle MR, Walley AY, Taylor JL. Effect of police action on low-barrier substance use disorder service utilization. Harm Reduct J. 2022 Jul 29; 19(1):86. PMID: 35906660.

    Read at: PubMed
  • Published on 6/23/2022

    Kim TW, Samet JH, Lodi S, Kimmel SD, Forman LS, Lira MC, Liebschutz JM, Williams EC, Walley AY. Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications. AIDS Behav. 2022 Jun 23. PMID: 35737281.

    Read at: PubMed
  • Published on 5/14/2022

    Taylor JL, Laks J, Christine PJ, Kehoe J, Evans J, Kim TW, Farrell NM, White CS, Weinstein ZM, Walley AY. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022 Jul 01; 236:109497. PMID: 35607834.

    Read at: PubMed
  • Published on 4/13/2022

    Slocum S, Ozga JE, Joyce R, Walley AY, Pollini RA. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study. BMC Public Health. 2022 Apr 13; 22(1):735. PMID: 35418048.

    Read at: PubMed
  • Published on 4/12/2022

    Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 Sep; 117(9):2450-2461. PMID: 35315162.

    Read at: PubMed
  • Published on 4/3/2022

    Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 Oct; 117(10):2635-2648. PMID: 35315148.

    Read at: PubMed
  • Published on 4/1/2022

    Jawa R, Murray S, Tori M, Bratberg J, Walley A. Federal Policymakers Should Urgently and Greatly Expand Naloxone Access. Am J Public Health. 2022 Apr; 112(4):558-561. PMID: 35319955.

    Read at: PubMed
  • Published on 3/19/2022

    Pollini RA, Slocum S, Ozga JE, Joyce R, Xuan Z, Green TC, Walley AY. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program. J Am Pharm Assoc (2003). 2022 Sep-Oct; 62(5):1546-1554. PMID: 35450833.

    Read at: PubMed

View 175 more publications: View full profile at BUMC

View all profiles